Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study – IL PSO (Italian Landscape Psoriasis)

Abstract: Background/Objectives: Brodalumab is a monoclonal antibody against the anti-IL-17 receptor A, approved for patients with moderate-to-severe psoriasis. This retrospective study investigated patients in clinical practice to assess the impact of body weight and previous treatments with biologics on the effectiveness of brodalumab. Methods: Patients were treated according to clinical practice, and assessed at baseline, 16, 36 and 52 weeks by means of the Psoriasis Area Severity Index (PASI) and DLQI score. Overall, 299 patients were included (147 naïve to biologics). Results: Mean PASI was significantly reduced compared with the baseline in the overall population by week 4 and continued to decrease at each study time point (15.9 ± 7.9 at baseline, 5.4 ± 5.3 at week 4, 1.9 ± 3.6 at week 6, 1.0 ± 2.1 at week 36, and 0.8 ± 2.1 at week 52; p < 0.001 at each control). PASI improved significantly both in bio-naïve and bio-experienced patients (p < 0.001). The proportions of patients achieving PASI 75, PASI 90, and PASI 100 were comparable between the bio-naïve and bio-experienced groups at all time points. The percentages of patients who achieved PASI 75 were similar in obese and non-obese subjects at all determinations except the visit performed after 36 weeks of treatment (94.3% non-obese vs. 83.1% obese, p = 0.005). PASI 90 was achieved more frequently among non-obese patients than obese patients after 36 weeks (80.7% vs. 64.4%, p = 0.008) and 52 weeks of treatment (84.1% vs. 71.7%, 0.027). The probability of achieving PASI 75 and PASI 100 was independent of nutritional status at any time during the study. Conclusions: In conclusion, our results confirm that brodalumab has both rapid and sustained effectiveness in patients with moderate-to-severe psoriasis; our results could be extended to patients with multiple risk factors impairing treatment response, such as multiple biological failure and obesity.

Authors

Institutions

Publication Details

Journal
Journal of Dermatological Treatment
Published
2025-02-06
DOI
https://doi.org/10.1080/09546634.2025.2452948
Citations
3
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
2.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study – IL PSO (Italian Landscape Psoriasis)

Diego Orsini, Giovanni Carlo Lazzaro Danzuso, Luca Bianchi, F. Graziola et al.
3 citations
Journal of Dermatological Treatment
Psoriasis: Treatment and Pathogenesis
2.39
article

Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study – IL PSO (Italian Landscape Psoriasis)

Diego Orsini, Giovanni Carlo Lazzaro Danzuso, Luca Bianchi, F. Graziola, Vincenzo Panasiti, Agostina Legori, Andrea Muracchioli, Maria Rita Carriero, Anna Elisabetta Cagni, G. Baggini, Maria Esposito, Annunziata Dattola, Claudio Guarneri, Emanuele Cozzani, Leonardo Zichichi, Federica Mola, Massimo Travaglini, Piergiorgio Malagoli, Andrea Musumeci, Marco Rubatto, Paolo Romita, Gianluca Calianno, Oriele Sarno, Marco Galluzzo, Antonio Costanzo, Giacomo Dal Bello, Maria Concetta Fargnoli, Martina Burlando, A Campanati, Dario Graceffa, Paolo Pella, Luisa Arancio, Elizabeth-Anne Campione, Elena De Col, Franco Cona, Gaia Moretta, Fabrizio Vaira, Riccardo Balestri, A. Carpentieri, C. S. Fiorella, Giacomo Caldarola, Andrea Carugno, Marianna Donnarumma, Alessandra Narcisi, Daniele Rizzo, Gianluca Pagnanelli, Alexandra Maria Giovanna Brunasso, M. Licciardello, Federico Diotallevi, Eugenio Provenzano, Antonio Di Tano, Maria L. Musumeci, Davide Strippoli
article en
3 citations

Abstract

Abstract: Background/Objectives: Brodalumab is a monoclonal antibody against the anti-IL-17 receptor A, approved for patients with moderate-to-severe psoriasis. This retrospective study investigated patients in clinical practice to assess the impact of body weight and previous treatments with biologics on the effectiveness of brodalumab. Methods: Patients were treated according to clinical practice, and assessed at baseline, 16, 36 and 52 weeks by means of the Psoriasis Area Severity Index (PASI) and DLQI score. Overall, 299 patients were included (147 naïve to biologics). Results: Mean PASI was significantly reduced compared with the baseline in the overall population by week 4 and continued to decrease at each study time point (15.9 ± 7.9 at baseline, 5.4 ± 5.3 at week 4, 1.9 ± 3.6 at week 6, 1.0 ± 2.1 at week 36, and 0.8 ± 2.1 at week 52; p < 0.001 at each control). PASI improved significantly both in bio-naïve and bio-experienced patients (p < 0.001). The proportions of patients achieving PASI 75, PASI 90, and PASI 100 were comparable between the bio-naïve and bio-experienced groups at all time points. The percentages of patients who achieved PASI 75 were similar in obese and non-obese subjects at all determinations except the visit performed after 36 weeks of treatment (94.3% non-obese vs. 83.1% obese, p = 0.005). PASI 90 was achieved more frequently among non-obese patients than obese patients after 36 weeks (80.7% vs. 64.4%, p = 0.008) and 52 weeks of treatment (84.1% vs. 71.7%, 0.027). The probability of achieving PASI 75 and PASI 100 was independent of nutritional status at any time during the study. Conclusions: In conclusion, our results confirm that brodalumab has both rapid and sustained effectiveness in patients with moderate-to-severe psoriasis; our results could be extended to patients with multiple risk factors impairing treatment response, such as multiple biological failure and obesity.

Journal of Dermatological TreatmentVol. 36(1)
Università Cattolica del Sacro Cuore (IT), University of Messina (IT), University of Insubria (IT), University of Rome Tor Vergata (IT), Marche Polytechnic University (IT), Morpho (United States) (US), University of Milan (IT), University of L'Aquila (IT), Association for Symbolic Logic (US), Martin University (US), Agostino Gemelli University Polyclinic (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), University of Catania (IT), IRCCS Policlinico San Donato (IT), Azienda Ospedaliera di Cosenza (IT), Ospedale A. Perrino (IT), Ospedale Sant Antonio (IT), Ospedale Garibaldi (IT), Azienda Ospedaliera S.Giuseppe Moscati (IT), IRCCS Ospedale Galeazzi - Sant'Ambrogio (IT), Alessandro Manzoni Hospital (IT), Ospedale Koelliker (IT), Istituto Dermopatico dell'Immacolata (IT), CTO Andrea Alesini (IT), Azienda Socio Sanitaria Territoriale Lariana (IT), Psoriasis Association (GB), Policlinico Universitario di Catania (IT), IRCCS Ospedale San Raffaele (IT), San Gallicano Hospital (IT), Campus Bio Medico University Hospital (IT), University of the Sacred Heart (JP), Ospedale degli Infermi (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Villa Torri Hospital (IT), IRCCS Humanitas Research Hospital (IT), University of Turin (IT), University of Bari Aldo Moro (IT), University of Genoa (IT), Sapienza University of Rome (IT)
Openalex Percentile: Top 13%
Psoriasis: Treatment and Pathogenesis
2.39
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.